{"hands_on_practices": [{"introduction": "The journey of a signal begins at the cell surface. Before a cell can respond to a morphogen like Activin or BMP, the ligand must effectively engage its receptors. This first practice invites you to apply fundamental principles of chemical kinetics to quantify this initial step, translating abstract concentrations into the number of active receptor complexes on a single cell. By calculating receptor occupancy and identifying the limiting component for signaling complex assembly [@problem_id:2683637], you will develop a quantitative intuition for how cellular context and receptor stoichiometry shape the initial signal reception.", "problem": "A dimeric ligand of the Transforming Growth Factor-$\\beta$ (TGF-$\\beta$) superfamily, such as Activin A, signals by assembling heteromeric complexes of type I and type II serine/threonine kinase receptors at the cell surface. Consider a single cell expressing a total of $5{,}000$ type I receptors and $10{,}000$ type II receptors on its plasma membrane. The extracellular ligand concentration is $0.5$ nM, and the apparent dissociation constant ($K_d$) for ligand binding to either receptor subtype in isolation is $1$ nM. Assume the following: (i) the system is at steady state, (ii) ligand is not appreciably depleted by binding to this cell so that the free ligand concentration remains equal to the bulk concentration, (iii) each receptor binds ligand monovalently with the same apparent $K_d$, and (iv) a signaling-competent complex requires $2$ ligand-bound type I receptors and $2$ ligand-bound type II receptors per ligand dimer (a heterotetramer).\n\nStarting from the law of mass action for a reversible binding reaction $R + L \\rightleftharpoons RL$ and the definition $K_d = \\frac{[R][L]}{[RL]}$, derive the equilibrium fractional occupancy for a receptor pool at ligand concentration $[L]$. Use this to estimate the fractional occupancy of each receptor subtype at $[L] = 0.5$ nM and $K_d = 1$ nM. Compute the expected numbers of ligand-bound type I and type II receptors on the cell. Identify which receptor subtype is limiting for assembly of heterotetrameric signaling complexes, given the $2{:}2$ stoichiometry. Finally, report the expected number of signaling-competent heterotetrameric complexes per cell implied by these occupancies.\n\nRound your final numeric answer to four significant figures. Express the final answer as a pure number (no units).", "solution": "The problem requires a quantitative analysis of receptor-ligand interactions and subsequent complex formation based on the law of mass action. The validity of the problem statement must first be established.\n\n**Problem Validation:**\nThe explicit givens are:\nTotal number of type I receptors, $N_{R_I, tot} = 5000$.\nTotal number of type II receptors, $N_{R_{II}, tot} = 10000$.\nLigand concentration, $[L] = 0.5$ nM.\nDissociation constant for ligand binding to either receptor, $K_d = 1$ nM.\nAssumptions: (i) the system is at steady state; (ii) free ligand concentration $[L]$ is constant and equal to the bulk concentration; (iii) each receptor binds the ligand dimer via a monovalent interaction described by the given $K_d$; (iv) a signaling-competent complex requires $2$ ligand-bound type I receptors and $2$ ligand-bound type II receptors per ligand dimer.\n\nThe problem is scientifically grounded in fundamental principles of chemical kinetics and receptor theory. The parameter values are biologically plausible. The problem is well-posed, providing sufficient information to determine a unique solution. The assumptions, while simplifying the true multi-step, cooperative nature of TGF-$\\beta$ receptor complex assembly, are explicitly stated and create a self-consistent, tractable mathematical model. Such simplifications are standard in biophysical modeling for pedagogical purposes. The problem is therefore deemed valid.\n\n**Step 1: Derivation of the Fractional Occupancy Equation**\nWe start from the reversible binding reaction for a receptor $R$ and a ligand $L$:\n$$ R + L \\rightleftharpoons RL $$\nThe dissociation constant, $K_d$, is defined by the concentrations at equilibrium:\n$$ K_d = \\frac{[R][L]}{[RL]} $$\nHere, $[R]$ is the concentration of free receptor, $[L]$ is the concentration of free ligand, and $[RL]$ is the concentration of the receptor-ligand complex. The total concentration of receptors, $[R_{tot}]$, is the sum of the free and bound forms:\n$$ [R_{tot}] = [R] + [RL] $$\nThe fractional occupancy, $\\theta$, is the fraction of total receptors that are ligand-bound:\n$$ \\theta = \\frac{[RL]}{[R_{tot}]} $$\nTo express $\\theta$ as a function of $[L]$ and $K_d$, we first rearrange the $K_d$ expression to solve for $[R]$:\n$$ [R] = \\frac{K_d [RL]}{[L]} $$\nWe substitute this into the equation for the total receptor concentration:\n$$ [R_{tot}] = \\frac{K_d [RL]}{[L]} + [RL] = [RL] \\left( \\frac{K_d}{[L]} + 1 \\right) = [RL] \\left( \\frac{K_d + [L]}{[L]} \\right) $$\nBy rearranging this result, we can solve for the ratio $\\frac{[RL]}{[R_{tot}]}$, which is the fractional occupancy $\\theta$:\n$$ \\theta = \\frac{[L]}{K_d + [L]} $$\nThis is the required expression for fractional occupancy.\n\n**Step 2: Calculation of Receptor Occupancies and Numbers of Bound Receptors**\nThe problem states that the ligand concentration is $[L] = 0.5$ nM and the dissociation constant is $K_d = 1$ nM. Since both type I ($R_I$) and type II ($R_{II}$) receptors are assumed to bind the ligand with the same $K_d$, their fractional occupancies, $\\theta_I$ and $\\theta_{II}$, will be identical.\n$$ \\theta_I = \\theta_{II} = \\frac{[L]}{K_d + [L]} = \\frac{0.5}{1 + 0.5} = \\frac{0.5}{1.5} = \\frac{1}{3} $$\nThus, at steady state, one-third of all receptors of each type are expected to be bound to a ligand.\n\nNext, we calculate the expected number of ligand-bound receptors for each subtype on the cell surface.\nThe total number of type I receptors is $N_{R_I, tot} = 5000$. The expected number of ligand-bound type I receptors, $N_{R_I L}$, is:\n$$ N_{R_I L} = N_{R_I, tot} \\times \\theta_I = 5000 \\times \\frac{1}{3} = \\frac{5000}{3} $$\nThe total number of type II receptors is $N_{R_{II}, tot} = 10000$. The expected number of ligand-bound type II receptors, $N_{R_{II} L}$, is:\n$$ N_{R_{II} L} = N_{R_{II}, tot} \\times \\theta_{II} = 10000 \\times \\frac{1}{3} = \\frac{10000}{3} $$\n\n**Step 3: Identification of Limiting Receptor and Calculation of Signaling Complexes**\nA signaling-competent complex requires a stoichiometry of $2$ ligand-bound type I receptors and $2$ ligand-bound type II receptors. We must determine the maximum number of such heterotetrameric complexes, $N_c$, that can be assembled from the available pools of bound receptors. This is a problem of a limiting reactant.\n\nThe number of complexes is limited by the component that is exhausted first. We can calculate the maximum number of complexes that could be formed given the number of bound receptors of each type.\nThe number of complexes supportable by the pool of bound type I receptors is the number of available bound receptors divided by the stoichiometry per complex ($2$):\n$$ N_{c,max,I} = \\frac{N_{R_I L}}{2} = \\frac{5000/3}{2} = \\frac{5000}{6} = \\frac{2500}{3} $$\nSimilarly, the number of complexes supportable by the pool of bound type II receptors is:\n$$ N_{c,max,II} = \\frac{N_{R_{II} L}}{2} = \\frac{10000/3}{2} = \\frac{10000}{6} = \\frac{5000}{3} $$\nThe expected number of complexes that can actually form, $N_c$, is the minimum of these two capacities:\n$$ N_c = \\min(N_{c,max,I}, N_{c,max,II}) = \\min\\left(\\frac{2500}{3}, \\frac{5000}{3}\\right) = \\frac{2500}{3} $$\nBecause $N_{c,max,I}  N_{c,max,II}$, the formation of signaling complexes is limited by the availability of ligand-bound type I receptors. Thus, the type I receptor is the limiting subtype in this system.\n\nFinally, we express the expected number of signaling complexes as a numerical value, rounded to four significant figures as requested.\n$$ N_c = \\frac{2500}{3} \\approx 833.333... $$\nRounding this value to four significant figures gives $833.3$. This represents the expected number of signaling-competent heterotetrameric complexes per cell under the given conditions and modeling assumptions.", "answer": "$$\\boxed{833.3}$$", "id": "2683637"}, {"introduction": "Once a signal is received, the cell faces a critical challenge: ensuring the signal is routed down the correct intracellular path. The TGF-β superfamily employs distinct Smad pathways for different ligands, and this problem explores the molecular basis of that specificity. Through the classic thought experiment of a domain swap [@problem_id:2683687], you will dissect how a small protein motif, the L45 loop, acts as a 'gatekeeper' to direct signaling traffic, illustrating the elegant modularity of protein design in achieving signaling fidelity.", "problem": "A central question in Transforming Growth Factor-$\\beta$ (TGF-$\\beta$) superfamily signaling is how type I receptors choose which receptor-regulated Smads (R-Smads) to phosphorylate. Consider the following well-established base:\n\n- Canonical TGF-β superfamily signaling proceeds when a dimeric ligand brings together type II and type I serine/threonine kinase receptors. The type II receptor phosphorylates the glycine-serine-rich (GS) domain of the type I receptor, activating its kinase. The activated type I receptor then phosphorylates R-Smads on their C-terminal Ser-Ser-X-Ser motif. R-Smads segregate into two classes: the Activin/Nodal/TGF-β branch signals primarily through $Smad2/3$ via type I receptors such as Activin receptor-like kinase (ALK)$4$, $ALK5$, and $ALK7$, whereas the Bone Morphogenetic Protein (BMP) branch signals primarily through $Smad1/5/8$ via type I receptors such as $ALK1$, $ALK2$, $ALK3$, and $ALK6$.\n- Specificity of R-Smad recruitment and phosphorylation is encoded by complementary docking surfaces: a short surface-exposed sequence on the type I receptor kinase domain known as the L45 loop, and the Mad Homology (MH2) L3 loop on R-Smads. The L45 loop differs between Activin/TGF-β-class receptors and BMP-class receptors and mediates selective binding to $Smad2/3$ versus $Smad1/5/8$, respectively.\n\nYou engineer two chimeric type I receptors in which only the L45 loop is swapped:\n- Chimera A: $ALK4$ in which the native L45 loop is replaced by the L45 loop sequence from $ALK6$.\n- Chimera B: $ALK6$ in which the native L45 loop is replaced by the L45 loop sequence from $ALK4$.\n\nAll other receptor features (ligand-binding cooperation with appropriate type II receptors, GS domain, kinase active site, juxtamembrane regions) are intact and unaltered, and cells express the relevant type II receptors for both Activin and BMP ligands. You stimulate cells expressing each chimera separately with saturating Activin A or $BMP7$ and assay C-terminal phosphorylation and nuclear accumulation of $Smad2/3$ and $Smad1/5/8$.\n\nWhich prediction best follows from the base principles above regarding how the L45 loop dictates R-Smad specificity?\n\nA. Swapping the L45 loops will invert R-Smad specificity: $ALK4$(L45 from $ALK6$) will recruit and phosphorylate $Smad1/5/8$ in response to Activin A, and $ALK6$(L45 from $ALK4$) will recruit and phosphorylate $Smad2/3$ in response to $BMP7$, with minimal phosphorylation of the noncognate R-Smad class in each case.\n\nB. Swapping the L45 loops will have no effect on R-Smad specificity because the catalytic cleft of the kinase dictates substrate choice; $ALK4$ will continue to phosphorylate $Smad2/3$ and $ALK6$ will continue to phosphorylate $Smad1/5/8$ regardless of the L45 loop.\n\nC. Swapping the L45 loops will abolish signaling by disrupting GS domain phosphorylation, preventing any R-Smad phosphorylation even in the presence of ligand.\n\nD. Swapping the L45 loops will render both receptors promiscuous, leading to robust phosphorylation of both $Smad2/3$ and $Smad1/5/8$ by each chimera irrespective of which ligand is applied.", "solution": "The problem statement must first be validated for scientific and logical integrity.\n\n### Step 1: Extract Givens\nThe problem statement provides the following information:\n1.  **Canonical Signaling Pathway**: Transforming Growth Factor Beta (TGF-β) superfamily signaling is initiated by a dimeric ligand binding to a complex of type II and type I serine/threonine kinase receptors.\n2.  **Activation Mechanism**: The type II receptor phosphorylates the glycine-serine-rich (GS) domain of the type I receptor, which activates the type I receptor kinase.\n3.  **Substrate Phosphorylation**: The activated type I receptor phosphorylates Receptor-Regulated Smads (R-Smads) on a C-terminal `Ser-Ser-X-Ser` motif.\n4.  **Signaling Branches**: There are two primary R-Smad branches:\n    *   The Activin/Nodal/TGF-β branch utilizes $Smad2/3$ and is mediated by type I receptors $ALK4, ALK5, and ALK7$.\n    *   The Bone Morphogenetic Protein (BMP) branch utilizes $Smad1/5/8$ and is mediated by type I receptors $ALK1, ALK2, ALK3, and ALK6$.\n5.  **Specificity Determinant**: The specificity of R-Smad phosphorylation is determined by the interaction between the L45 loop of the type I receptor kinase domain and the Mad Homology 2 (MH2) L3 loop on the R-Smad. This interaction is described as selective binding via complementary docking surfaces.\n6.  **Chimeric Constructs**: Two chimeric receptors are engineered:\n    *   Chimera A: $ALK4$ with its native L45 loop replaced by the L45 loop from $ALK6$.\n    *   Chimera B: $ALK6$ with its native L45 loop replaced by the L45 loop from $ALK4$.\n7.  **Experimental Conditions**: All other receptor domains are unaltered. Cells express necessary type II receptors. Stimulation is performed with saturating concentrations of either Activin A or $BMP7$. The assay measures C-terminal phosphorylation and nuclear accumulation of $Smad2/3$ and $Smad1/5/8$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is evaluated against the validation criteria.\n*   **Scientifically Grounded**: The problem statement accurately describes the established principles of TGF-β superfamily signaling. The roles of the receptors ($ALK4$, $ALK6$), ligands (Activin A, $BMP7$), R-Smads ($Smad2/3$, $Smad1/5/8$), and the L45 loop as a key specificity determinant are consistent with current knowledge in molecular and developmental biology.\n*   **Well-Posed**: The problem is clearly structured. It presents a set of established principles and a hypothetical experiment (a domain-swap), then asks for a logical prediction based on those principles. The setup is self-contained and sufficient information is provided to deduce a unique answer.\n*   **Objective**: The language is precise and technical, free of subjectivity or ambiguity.\n\nThe problem does not violate any of the invalidity criteria. It is scientifically sound, formally structured, and requires logical deduction from given premises.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution will be derived.\n\n### Derivation of the Correct Answer\n\nThe solution is deduced by applying the given principles to the two engineered chimeras. The central premise is that ligand specificity is endowed by the receptor's extracellular domain (part of the main receptor \"body\"), while R-Smad substrate specificity is endowed by the L45 loop of the intracellular kinase domain.\n\n**Analysis of Chimera A: $ALK4$(L45 from $ALK6$)**\n1.  **Ligand Recognition and Activation**: The body of this receptor is $ALK4$. $ALK4$ is an Activin-type receptor. Therefore, it will be activated by its cognate ligand, Activin A, in conjunction with the appropriate type II receptor. It will not be activated by $BMP7$, which is a BMP-type ligand. Upon binding Activin A, the associated type II receptor will phosphorylate the intact GS domain of Chimera A, activating its kinase.\n2.  **R-Smad Recruitment and Phosphorylation**: The L45 loop of Chimera A is from $ALK6$. $ALK6$ is a BMP-type receptor whose L45 loop selectively recruits $Smad1/5/8$. Therefore, the activated kinase of Chimera A will recruit and phosphorylate $Smad1/5/8$, not its native substrate $Smad2/3$.\n3.  **Predicted Outcome for Chimera A**: Stimulation with Activin A will lead to phosphorylation of $Smad1/5/8$. Stimulation with $BMP7$ will produce no signaling through this chimera.\n\n**Analysis of Chimera B: $ALK6$(L45 from $ALK4$)**\n1.  **Ligand Recognition and Activation**: The body of this receptor is $ALK6$. $ALK6$ is a BMP-type receptor. It will be activated by its cognate ligand, $BMP7$. It will not be activated by Activin A. Upon binding $BMP7$, the associated type II receptor will phosphorylate the intact GS domain of Chimera B, activating its kinase.\n2.  **R-Smad Recruitment and Phosphorylation**: The L45 loop of Chimera B is from $ALK4$. $ALK4$ is an Activin-type receptor whose L45 loop selectively recruits $Smad2/3$. Therefore, the activated kinase of Chimera B will recruit and phosphorylate $Smad2/3$, not its native substrate $Smad1/5/8$.\n3.  **Predicted Outcome for Chimera B**: Stimulation with $BMP7$ will lead to phosphorylation of $Smad2/3$. Stimulation with Activin A will produce no signaling through this chimera.\n\nIn summary, the swap of the L45 loop inverts the R-Smad specificity of each receptor while preserving its original ligand specificity.\n\n### Option-by-Option Analysis\n\n**A. Swapping the L45 loops will invert R-Smad specificity: $ALK4$(L45 from $ALK6$) will recruit and phosphorylate $Smad1/5/8$ in response to Activin A, and $ALK6$(L45 from $ALK4$) will recruit and phosphorylate $Smad2/3$ in response to $BMP7$, with minimal phosphorylation of the noncognate R-Smad class in each case.**\nThis option aligns perfectly with our derivation. Activin A activates the $ALK4$ body, which then uses the $ALK6$ L45 loop to phosphorylate $Smad1/5/8$. $BMP7$ activates the $ALK6$ body, which then uses the $ALK4$ L45 loop to phosphorylate $Smad2/3$. This is a direct consequence of the principles stated in the problem.\n**Verdict: Correct.**\n\n**B. Swapping the L45 loops will have no effect on R-Smad specificity because the catalytic cleft of the kinase dictates substrate choice; $ALK4$ will continue to phosphorylate $Smad2/3$ and $ALK6$ will continue to phosphorylate $Smad1/5/8$ regardless of the L45 loop.**\nThis option contradicts a fundamental premise of the problem: that \"Specificity of R-Smad recruitment and phosphorylation is encoded by... the L45 loop\". It proposes an alternative mechanism for specificity (the catalytic cleft) that is not supported by the given information.\n**Verdict: Incorrect.**\n\n**C. Swapping the L45 loops will abolish signaling by disrupting GS domain phosphorylation, preventing any R-Smad phosphorylation even in the presence of ligand.**\nThis is factually incorrect based on the problem description. The L45 loop is part of the kinase domain, which is spatially and functionally distinct from the juxtamembrane GS domain. The problem explicitly states the GS domain is \"intact and unaltered\". Activation of the kinase via GS domain phosphorylation by the type II receptor should proceed normally.\n**Verdict: Incorrect.**\n\n**D. Swapping the L45 loops will render both receptors promiscuous, leading to robust phosphorylation of both $Smad2/3$ and $Smad1/5/8$ by each chimera irrespective of which ligand is applied.**\nThis option contains two errors. First, it negates the principle of selective binding mediated by the L45 loop, incorrectly predicting promiscuity instead of a shift in specificity. Second, it incorrectly claims signaling will occur \"irrespective of which ligand is applied,\" ignoring that ligand specificity is determined by the receptor's extracellular domain, which was not swapped. $ALK4$ will still only respond to Activin-type ligands, and $ALK6$ will still only respond to BMP-type ligands.\n**Verdict: Incorrect.**", "answer": "$$\\boxed{A}$$", "id": "2683687"}, {"introduction": "The ultimate goal of most developmental signaling pathways is to orchestrate a precise pattern of gene expression. This response is rarely linear; instead, cells often exhibit switch-like behavior, abruptly changing their transcriptional state above a certain signal threshold. This final practice uses the Hill function to model this non-linear dose-response relationship [@problem_id:2683656]. By analyzing how transcriptional output changes with ligand concentration, you will gain insight into the concept of cooperativity and how it helps convert a smooth morphogen gradient into sharp, distinct domains of gene expression.", "problem": "In canonical Bone Morphogenetic Protein (BMP) signaling, dimeric BMP ligands engage Type I and Type II serine/threonine kinase receptors to form a signaling complex that phosphorylates receptor-regulated Small Mothers Against Decapentaplegic (Smad) proteins, culminating in transcriptional activation of target genes. For promoters that integrate Smad occupancy with cooperative recruitment of cofactors, the steady-state, normalized transcriptional output as a function of extracellular BMP concentration $c$ can be empirically modeled by a Hill input-output function with Hill coefficient $n$, \n$$\nf(c)=\\frac{c^{n}}{K^{n}+c^{n}},\n$$\nwhere $K$ is the concentration at which the output is half-maximal. Assume $n=2$, consistent with a minimal cooperative step due to receptor complex assembly or coactivator recruitment.\n\nBeginning from the definition above and the notion of fold-change in gene expression as a ratio of outputs at two concentrations, compute the fold-change $F$ in normalized gene expression when the BMP concentration doubles from $c=K$ to $c=2K$. That is, evaluate \n$$\nF=\\frac{f(2K)}{f(K)}\n$$\nfor $n=2$. Provide your answer as an exact value (no rounding). The fold-change is dimensionless; report the final answer without units.", "solution": "The problem will first be subjected to a rigorous validation to ascertain its scientific and logical integrity.\n\nThe givens are stated as follows:\n1.  The steady-state, normalized transcriptional output as a function of concentration $c$ is given by the Hill function: $f(c)=\\frac{c^{n}}{K^{n}+c^{n}}$.\n2.  $K$ is the concentration at which the output is half-maximal.\n3.  The Hill coefficient is specified as $n=2$.\n4.  The fold-change $F$ in gene expression is defined as the ratio of outputs at two concentrations.\n5.  The specific task is to compute the fold-change $F=\\frac{f(2K)}{f(K)}$.\n\nThe problem is evaluated against the validation criteria:\n-   **Scientific Grounding**: The problem is grounded in established principles of molecular biology and biochemistry. The Hill equation is a standard mathematical model used to describe cooperative binding phenomena and dose-response curves, which is entirely appropriate for modeling the transcriptional response to a signaling ligand like BMP. The choice of $n=2$ reflects a minimal cooperative system, consistent with, for example, the dimerization of receptors necessary for signaling complex formation. The premise is scientifically sound and well-established.\n-   **Well-Posedness**: The problem is well-posed. It provides a specific mathematical function, all necessary parameters ($n=2$), and the explicit concentrations for evaluation ($c=K$ and $c=2K$). The task is clearly defined, and a unique, stable solution can be determined through direct calculation.\n-   **Objectivity**: The problem is stated in objective, formal language, free of any subjective or ambiguous terminology.\n-   **Completeness and Consistency**: The problem is self-contained and provides all information required for its solution. There are no contradictions in the provided data or definitions.\n\nThe verdict is that the problem is **valid**. It is a straightforward application of a standard biophysical model. A solution will now be be derived.\n\nThe transcriptional output function is given by:\n$$\nf(c)=\\frac{c^{n}}{K^{n}+c^{n}}\n$$\nWe are given the Hill coefficient $n=2$. Substituting this value into the function yields:\n$$\nf(c)=\\frac{c^{2}}{K^{2}+c^{2}}\n$$\nThe problem requires the computation of the fold-change $F$, defined as the ratio of the transcriptional output at concentration $c=2K$ to the output at concentration $c=K$.\n$$\nF = \\frac{f(2K)}{f(K)}\n$$\nFirst, we evaluate the function at $c=K$:\n$$\nf(K) = \\frac{K^{2}}{K^{2}+K^{2}} = \\frac{K^{2}}{2K^{2}} = \\frac{1}{2}\n$$\nThis result is consistent with the definition of $K$ as the concentration yielding half-maximal output. The maximal output of this normalized function is $1$, which is approached as $c \\rightarrow \\infty$.\n\nNext, we evaluate the function at $c=2K$:\n$$\nf(2K) = \\frac{(2K)^{2}}{K^{2}+(2K)^{2}} = \\frac{4K^{2}}{K^{2}+4K^{2}} = \\frac{4K^{2}}{5K^{2}} = \\frac{4}{5}\n$$\nNow, we compute the fold-change $F$ by taking the ratio of these two values:\n$$\nF = \\frac{f(2K)}{f(K)} = \\frac{\\frac{4}{5}}{\\frac{1}{2}}\n$$\nTo simplify this complex fraction, we multiply the numerator by the reciprocal of the denominator:\n$$\nF = \\frac{4}{5} \\times \\frac{2}{1} = \\frac{8}{5}\n$$\nThe fold-change in normalized gene expression when the BMP concentration doubles from $c=K$ to $c=2K$ for a system with a Hill coefficient of $n=2$ is $\\frac{8}{5}$. This can also be expressed as $1.6$. The question requires an exact value, for which the fractional form is precise and sufficient.", "answer": "$$\\boxed{\\frac{8}{5}}$$", "id": "2683656"}]}